©2018 Immunicom, Inc. All rights reserved.

6048 CORNERSTONE COURT W

SUITE D, 

SAN DIEGO, CA 92121

  • Black LinkedIn Icon

SCIENTIFIC PUBLICATIONS

White Paper

 

Immunicom's White Paper entails a more scientific explanation of Immunicom's therapeutic approach and further background behind the science. 

Journal of Translational Medicine: Unleashing endogenous TNF-alpha as a cancer immunotherapeutic

Immunicom is excited to share a personally invited peer-reviewed article by the Journal of Translational Medicine. This Hot Topic article describes the scientific advancements of Immunicom's technology- authored by Immunicom's head scientist, Dr. Steven Josephs, and co-authors include Immunicom's CEO, CCO, and the Journal's Editor-in-Chief, Dr. Franco Marincola.

Canine Clinical Study Poster

 

Immunicom conducted clinical trials on over 300 canines and  overall,  50–60%  of  the  patients  treated  were  observed  to  have  either  stable  disease  or  partial  responses  by  RECIST Criteria during treatment with one patient having  experienced  a  complete  response  with  clearance  of  metastases.